Bio-Rad Laboratories (NYSE:BIO) Q3 results:
Revenue: $560.6M (+2.8%); Life Sciences: $215.7M (+4.5%); Clinical Diagnostics: $341.8M (+2.4%).
Net loss: ($258.8M) (-196.1%); non-GAAP net income:$48.6M (+76.1%); loss/share: ($8.68) (-197.6%); non-GAAP EPS: $1.61 (+76.9%).
Cash flow ops (9 mo.): $298.1M (+65.2%).
GAAP results negatively impacted by a decline of $390.6M in the market value of securities held primary related to its investment in Sartorius AG.
2019 guidance: Revenue growth: 4.0 – 4.5%.
Previously: Bio-Rad Labs EPS beats by $0.20, misses on revenue (Oct. 31)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.